[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endometrial-carcinoma-stage-i\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endometrial-carcinoma-stage-i":65},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100488976",false,"NCT05647109","Patient-derived Tumor-like Cell Clusters Predict Progesterone Sensitivity in Patients With Early Endometrial Cancer","Department of Obstetrics & Gynecology ，Peking University People's Hospital","Inclusion Criteria:\n\n* Have a confirmed pathological diagnosis based upon hysteroscopy: atypical endometrial hyperplasia or histologically prove well-differentiated EEC G1 without myometrial invasion\n* No signs of suspicious extrauterine involvement on enhanced magnetic resonance imaging (MRI) or enhanced computed tomography (CT) or ultrasound\n* Have a desire for remaining reproductive function or uterus\n* Good compliance with adjunctive treatment and follow-up\n\nExclusion Criteria:\n\n* Acute liver disease or liver tumor (benign or malignant) or renal dysfunction\n* Pregnancy or potential pregnancy\n* Confirmed diagnosis of any cancer in reproductive system\n* Acute severe disease such as stroke or heart infarction or a history of thrombosis disease\n* Hypersensitivity or contradiction for using MPA or MA\n* With other factors of reproductive dysfunction;\n* Strong request for uterine removal or other conservative treatment","FEMALE","17 Years","45 Years",{"count":19,"type":20},244,"ESTIMATED","1 Year","OBSERVATIONAL","To construct a prediction model of progesterone sensitivity in patients with endometrial cancer treated with fertility preservation",[25,26],"Endometrial Carcinoma Stage I","Atypical Endometrial Hyperplasia",[28,29,30],"Progesterone","Patient-derived tumor-like cell clusters","Endometrial Carcinoma","RECRUITING","2025-05-02",{"date":34,"type":35},"2025-05-04","ACTUAL",{"date":37,"type":35},"2021-09-01",{"date":39,"type":20},"2025-10-31",{"name":41,"class":42},"Peking University People's Hospital","OTHER",1,{"id":45,"slug":4,"hasResults":10,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":64,"locationsCount":43},"100491181","NCT05675787","Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia","Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Atypical Endometrial Hyperplasia and Early Endometrial Carcinoma","Inclusion Criteria:\n\n* Have a confirmed pathological diagnosis based upon hysteroscopy: histologically prove AEH or well-differentiated EEC G1 without myometrial invasion: 1. Untreated patients; 2. Patients with persistent lesions after one course (12 weeks) of progesterone therapy; 3. Patients who did not achieve complete remission after 2 courses (24 weeks) of progesterone therapy;\n* No signs of suspicious extrauterine involvement on enhanced magnetic resonance imaging (MRI) or enhanced computed tomography (CT) or ultrasound\n* Have a desire for remaining reproductive function or uterus\n* Good compliance with adjunctive treatment and follow-up\n\nExclusion Criteria:\n\n* Hypersensitivity or contradiction for using MPA or atorvastatin\n* Pregnancy or potential pregnancy\n* Confirmed diagnosis of any cancer in reproductive system\n* Already diagnosed with hyperlipidemia and using lipid-lowering drugs\n* Acute liver disease or liver tumor (benign or malignant) or renal dysfunction\n* Acute severe disease such as stroke or heart infarction or a history of thrombosis disease\n* With other factors of reproductive dysfunction;\n* Strong request for uterine removal or other conservative treatment\n* Smoker (\\>15 cigarettes a day)\n* Drinker (\\>20 grams a day)",{"count":51,"type":20},82,"INTERVENTIONAL",[54],"PHASE2","To explore the treatment efficacy of medroxyprogesterone acetate plus atorvastatin in patients with atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EEC) for conservative treatment.",[26,25],[30,26],"2024-07-09",{"date":60,"type":35},"2024-07-11",{"date":62,"type":35},"2023-01-06",{"date":39,"type":20},{"name":41,"class":42},""]